Comparative effectiveness and safety of first-line anti-TNF, vedolizumab, and ustekinumab in biologic-naïve Crohn's disease: Analysis from a real-world cohort. (PubMed, Dig Liver Dis) - Oct 4, 2026 - "First-line anti-TNF, VDZ, and UST showed no significant differences in 52-week clinical effectiveness or treatment persistence, supporting individualized treatment selection."
HEOR • Journal • Real-world evidence • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Oncology
|
|
Adam Goldman; Ahmad Albshesh; Bella Ungar; Hadas Yaakobi; Haim Leibovitzh; Haya Mushka Abitbol; Nitsan Maharshak; Offir Okashi; Ohad Regev; Shomron Ben-Horin; Uri Kopylov; Uria Shani
|